<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01159899</url>
  </required_header>
  <id_info>
    <org_study_id>MSC- AS3</org_study_id>
    <nct_id>NCT01159899</nct_id>
  </id_info>
  <brief_title>Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee</brief_title>
  <official_title>Pilot Study of A One-Step Procedure for the Use of Autologous Bone Marrow Mesenchymal Stem Cells Stimulated by Proteins Scaffold to Heal Under Arthroscopy Full-Thickness Defects Articular Cartilage and Osteoarthrosis of the Knee.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Marseille</source>
  <oversight_info>
    <authority>France: Afssaps - French Health Products Safety Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to investigate the efficacy and safety of autologous
      transplantation, under arthroscopy, of Bone Marrow Mesenchymal stem cells, using, with a
      cell separator, a fresh non-culture expanded Autologous Bone Marrow derived Mesenchymal
      Stem, mixed and activated with proteins scaffold in patient with Knee cartilage defects and
      osteoarthritis. Based on extensive preclinical investigations, the technology of using
      freshly isolated bone marrow mononuclear cells mixed with proteins seems safe and most
      effective for a one-step correction of cartilage defect and restoration of the osteochondral
       complex, because the same mixture can generate cartilage in the vasculature-free knee
      joint, and bone in the environment of bone defects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the implantation of the mesenchymal stem cells, a knee arthroscopy procedure is made
      for the debridement of the meniscal and cartilage lesions, with microperforation and
      abrasion, preparation of the osteochondral defect to receive the transplantation, patellar
      lateral release if necessary.

      Then, the investigators use a fresh non-culture expanded autologous bone marrow derived
      mesenchymal mononuclear stem cells, stimulated with a protein matrix and mixed in a collagen
      hydroxyapatite scaffold. This cellular paste is transplanted in the prepared defect, under
      arthroscopy, with injection of platelet rich plasma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>IKS, International Knee Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>measure assess of the knee function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IKS, International Knee Score</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>mesure assess of the knee function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICRS, International Cartilage Research Society</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>measure assess of the knee function and quality of the new cartilage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICRS, International Cartilage Research Society</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>measure assess of the knee function and quality of the new cartilage</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Knee Arthrosis</condition>
  <condition>Osteochondral Defects</condition>
  <condition>Osteochondritis Dissecans</condition>
  <condition>Osteonecrosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis</intervention_name>
    <description>Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure</description>
    <other_name>mesenchymal stem cells</other_name>
    <other_name>Knee Arthrosis</other_name>
    <other_name>Knee osteochondral defect</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active patients (30 to 70 years)

          -  An isolated osteochondral defect

          -  with cartilage on the opposing surface no more than grade 2 or 3 (ICRS
             classification), with 3/4 of meniscus present.

          -  Stable knee ; previous ligament reconstruction, if stable

          -  A defect that is 1 - 4 cm2 or more, up to 6 cm2, located on the femoral condyle, and
             IKS score &lt;75.

          -  Ability to understand and willingness to sign consent form

        Exclusion Criteria:

          -  Patients younger than 30 years and older than 70 years

          -  Diffuse and advanced articular cartilage degeneration of the joint

          -  Axial malalignment, meniscal pathology, and ligamentous instability are relative
             contraindications that have to be dealt with primarily either concomitantly or before
             the transplantation during 1 of the 2 stages of the procedure. Refusal of the patient
             to address these conditions in presence of a cartilage lesion is a criterion for
             exclusion from the study, to avoid the impact of these knee pathologies on the final
             results

          -  Kissing lesions (i.e., on both opposing surfaces of a joint).

          -  Existing infection in or around the joint &amp; lesions of infectious or oncologic
             etiology.

          -  Debilitated patients.

          -  Immunocompromised patients.

          -  Patients with autoimmune disorders &amp; systemic inflammatory disease.

          -  Preoperative poor neurological or vascular status of the affected limb.

          -  Specific contraindications include the use of tobacco and medications that may impair
             cell proliferation, such as NSAIDs and immunosuppressive drugs. Patients must be
             nicotine-free (stop smoking) prior to the procedure, as studies have shown that the
             oxidative effect of smoking impairs cell function and subsequent healing.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Assor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Knee and Lower Limb Institute, Marseille, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Assor, MD</last_name>
    <phone>0033611950518 / 0033609505060</phone>
    <email>michel.assor@free.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shimon Slavin, Pr</last_name>
    <email>slavin@CTCIcenter.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Knee and Lower Limb Institute, Dr Michel Assor</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Assor, MD</last_name>
      <phone>0033491221212 / 0033609505060</phone>
      <email>michel.assor@free.fr</email>
    </contact>
    <contact_backup>
      <last_name>Michel Assor, MD</last_name>
      <phone>0033611950518</phone>
    </contact_backup>
    <investigator>
      <last_name>Michel Assor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://arthrosport.com</url>
    <description>knee procedures</description>
  </link>
  <link>
    <url>http://cellulesouche-genou.blogspot.com</url>
    <description>knee stem cell procedures</description>
  </link>
  <link>
    <url>http://cellulesouches.org</url>
    <description>cell therapy and PRP</description>
  </link>
  <verification_date>September 2010</verification_date>
  <lastchanged_date>October 6, 2010</lastchanged_date>
  <firstreceived_date>July 6, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Michel Assor, MD</name_title>
    <organization>Knee and Lower Limb Institute, 92 Rue Commandant Rolland, 13008 Marseille, France</organization>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>knee arthritis</keyword>
  <keyword>Knee arthrosis</keyword>
  <keyword>articular cartilage defects</keyword>
  <keyword>osteochondral defects</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>stem cells</keyword>
  <keyword>cellules souches,</keyword>
  <keyword>genou</keyword>
  <keyword>arthrose genou</keyword>
  <keyword>PRP platelet rich plasma</keyword>
  <keyword>thérapie cellulaire</keyword>
  <keyword>implantation cellules souches mésenchymateuses</keyword>
  <keyword>régénération cartilage</keyword>
  <keyword>cicatrisation ménisque</keyword>
  <keyword>ligament</keyword>
  <keyword>plasma riche plaquettaire</keyword>
  <keyword>platelet rich plasma</keyword>
  <keyword>stem cell</keyword>
  <keyword>regrowt cartilage</keyword>
  <keyword>cellules souches</keyword>
  <keyword>PRP</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteochondritis</mesh_term>
    <mesh_term>Osteochondritis Dissecans</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
</clinical_study>
